The Journal of Urology
Volume 180, Issue 5 , Pages 2206-2211 , November 2008

The Significance of Monoamine Oxidase-A Expression in High Grade Prostate Cancer

Received 16 January 2008

References 

  1. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517
  2. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395
  3. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A. 2006;103:10991
  4. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295
  5. Zhao H, Nolley R, Chen Z, Reese SW, Peehl DM. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation. 2008;76:820
  6. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology. 2003;62:11
  7. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol. 2004;165:1543
  8. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157:1769
  9. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate? (an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody). Am J Surg Pathol. 2002;26:1151
  10. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246
  11. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68:1625
  12. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25:1696
  13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591
  14. Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, et al. Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer. 2004;112:121
  15. Aaltomaa S, Lipponen P, Viitanen J, Kankkunen JP, Ala-Opas M, Kosma VM. Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy. Eur Urol. 2000;38:555
  16. Carter HB, Isaacs WB. Improved biomarkers for prostate cancer: a definite need. J Natl Cancer Inst. 2004;96:813
  17. Toninello A, Pietrangeli P, De Marchi U, Salvi M, Mondovi B. Amine oxidases in apoptosis and cancer. Biochim Biophys Acta. 2006;1765:1
  18. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197

 Study received institutional review board approval.

 Supported by National Institutes of Health Grants 5 R01 CA121460 and 1 K01 CA123532.

PII: S0022-5347(08)01810-7

doi: 10.1016/j.juro.2008.07.019

The Journal of Urology
Volume 180, Issue 5 , Pages 2206-2211 , November 2008

Article Tools

* Image Usage & Resolution